Separately, BidaskClub upgraded Cellular Biomedicine Group from a hold rating to a buy rating in a report on Wednesday, January 10th.
Shares of Cellular Biomedicine Group (NASDAQ:CBMG) opened at $18.95 on Tuesday. Cellular Biomedicine Group has a fifty-two week low of $5.05 and a fifty-two week high of $22.75.
In other news, SVP Andrew K. Chan bought 8,333 shares of the firm’s stock in a transaction dated Friday, December 22nd. The stock was acquired at an average price of $12.00 per share, for a total transaction of $99,996.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Yihong Yao bought 4,167 shares of the firm’s stock in a transaction dated Friday, December 22nd. The shares were purchased at an average price of $12.00 per share, with a total value of $50,004.00. The disclosure for this purchase can be found here. Insiders have bought a total of 41,667 shares of company stock valued at $500,004 in the last quarter. Company insiders own 8.20% of the company’s stock.
A hedge fund recently bought a new stake in Cellular Biomedicine Group stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Cellular Biomedicine Group Inc (NASDAQ:CBMG) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,041 shares of the biotechnology company’s stock, valued at approximately $107,000. Zurcher Kantonalbank Zurich Cantonalbank owned 0.07% of Cellular Biomedicine Group as of its most recent SEC filing. 3.12% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Cellular Biomedicine Group (CBMG) Earns “Hold” Rating from Maxim Group” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3253545/cellular-biomedicine-group-cbmg-earns-hold-rating-from-maxim-group.html.
About Cellular Biomedicine Group
Cellular Biomedicine Group Inc is a United States-based company which is engaged in the development of cell therapy technologies. The Company develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the good manufacturing practices (GMP) laboratory.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.